SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (Pink Sheets:OVIT), reported that the AdnaTest BreastCancer Select & Detect kit, manufactured by AdnaGen AG (Langenhagen, Germany), is now available for research as well as for pay-out-of-pocket patients in the Czech Republic and Slovakia. The research team at the Czech Academy of Science and its spin-off company, TATAA Molecular Diagnostics, have conducted several research efforts with the goal to prove the capability of the CTC test to improve therapeutic decision making in several cancers.
